Analysts Set CG Oncology, Inc. (NASDAQ:CGON) PT at $83.18

CG Oncology, Inc. (NASDAQ:CGON) has earned a consensus rating of “Moderate Buy” from the fourteen brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $83.1818.

Several research firms have issued reports on CGON. Royal Bank Of Canada cut their price target on shares of CG Oncology from $81.00 to $79.00 and set an “outperform” rating for the company in a research report on Friday, August 7th. Wolfe Research initiated coverage on CG Oncology in a report on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Wedbush boosted their target price on CG Oncology from $77.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Truist Financial increased their target price on CG Oncology from $82.00 to $85.00 and gave the company a “buy” rating in a report on Friday, August 7th. Finally, Piper Sandler raised their price target on CG Oncology from $82.00 to $85.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th.

Insider Activity

In related news, Director James Mulay sold 24,165 shares of CG Oncology stock in a transaction on Friday, July 10th. The shares were sold at an average price of $75.16, for a total value of $1,816,241.40. Following the transaction, the director directly owned 24,165 shares of the company’s stock, valued at $1,816,241.40. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Leonard E. Post sold 1,000 shares of the company’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $74.54, for a total transaction of $74,540.00. Following the sale, the director owned 1,000 shares of the company’s stock, valued at $74,540. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 38,129 shares of company stock valued at $2,738,357. 4.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CG Oncology

A number of large investors have recently added to or reduced their stakes in the company. Fiduciary Financial Advisors bought a new position in shares of CG Oncology during the second quarter valued at about $28,000. NFSG Corp bought a new stake in shares of CG Oncology in the first quarter worth about $34,000. Comerica Bank increased its holdings in CG Oncology by 100.4% during the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after purchasing an additional 515 shares during the period. Fifth Third Bancorp purchased a new position in CG Oncology during the 1st quarter valued at about $74,000. Finally, KBC Group NV purchased a new position in CG Oncology during the 1st quarter valued at about $78,000. Institutional investors own 26.56% of the company’s stock.

CG Oncology Stock Performance

CGON stock opened at $78.42 on Friday. The company has a market capitalization of $6.95 billion, a PE ratio of -29.15 and a beta of 0.23. CG Oncology has a one year low of $26.04 and a one year high of $80.97. The company’s 50 day moving average price is $72.42 and its two-hundred day moving average price is $66.20.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.24). CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 25.20%. The business had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $0.36 million. On average, research analysts predict that CG Oncology will post -3.27 EPS for the current year.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.